Free Trial
NASDAQ:ENTO

Entero Therapeutics (ENTO) Stock Price, News & Analysis

Entero Therapeutics logo
$0.49 +0.00 (+0.62%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$0.49 0.00 (-0.20%)
As of 07/11/2025 07:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Entero Therapeutics Stock (NASDAQ:ENTO)

Key Stats

Today's Range
$0.46
$0.49
50-Day Range
$0.35
$0.59
52-Week Range
$0.19
$1.15
Volume
282,610 shs
Average Volume
827,890 shs
Market Capitalization
$2.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ENTO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Entero Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ENTO Stock News Headlines

Entero Therapeutics Inc ENTO
Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.
Entero Therapeutics Delays 10-K Filing
Entero Therapeutics names Richard Paolone as interim CEO
See More Headlines

ENTO Stock Analysis - Frequently Asked Questions

Entero Therapeutics' stock was trading at $0.6220 at the beginning of 2025. Since then, ENTO shares have decreased by 21.2% and is now trading at $0.49.

Entero Therapeutics, Inc. (NASDAQ:ENTO) announced its earnings results on Thursday, May, 15th. The company reported ($0.21) EPS for the quarter.

Shares of ENTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Entero Therapeutics investors own include Conduit Pharmaceuticals (CDT), BIOLASE (BIOL), Cyclacel Pharmaceuticals (CYCC), Dare Bioscience (DARE), PMGC (ELAB), TRACON Pharmaceuticals (TCON) and Tempest Therapeutics (TPST).

Company Calendar

Last Earnings
5/15/2025
Today
7/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ENTO
Previous Symbol
NASDAQ:ENTO
CIK
1604191
Fax
N/A
Employees
9
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$18.06 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-1,063.82%
Return on Assets
-26.06%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.90
Quick Ratio
2.90

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.82) per share
Price / Book
-0.60

Miscellaneous

Outstanding Shares
4,770,000
Free Float
4,730,000
Market Cap
$2.34 million
Optionable
N/A
Beta
0.84
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NASDAQ:ENTO) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners